A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen
Summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Eligibility
- Age range
- 50–105 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥50 years * Lp(a)≥ 200 nmol/L during screening * Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis Exclusion Criteria: * Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia) * Prior or planned arterial revascularization * History of major bleeding disorder
Interventions
- DrugOlpasiran
Olpasiran will be administered via SC injection.
- DrugPlacebo
Placebo will be administered via SC injection.
Locations (243)
- Advanced Cardiovascular LLCAlexander City, Alabama
- University of Alabama Birmingham Saint Vincents BirminghamBirmingham, Alabama
- Birmingham Clinical ResearchBirmingham, Alabama
- Alliance For Multispecialty Research - DaphneDaphne, Alabama
- Eastern Shore Research InstituteFairhope, Alabama
- Heart Center Research LLCHuntsville, Alabama